Cellprothera And BioCardia Partner On Phase 2 EXCELLENT Trial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MULHOUSE, France & SAN CARLOS, Calif.--(BUSINESS WIRE)--CellProThera® and BioCardia® today announced an agreement to partner on the EXCELLENT (Expanded Cell Endocardiac Transplantation) Trial, a multi-center, controlled Phase I/IIb study to evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process and delivered via the BioCardia Helix™ Transendocardial Delivery System.

The agreement calls for milestone payments to BioCardia, which are creditable to a future clinical development program, and milestone payments to CellProThera for timely completion of the Phase II study.

Help employers find you! Check out all the jobs and post your resume.

Back to news